Clinical trials: HIV Infection Asymptomatic
HIV Infections
Phase I Study of Alferon N Injection in Persons With Asymptomatic Human Immunodeficiency Virus (HIV) Infection
To determine the safety and tolerance of subcutaneous injections of natural interferon alpha (IFN) in asymptomatic HIV-positive persons and record its effects on the HIV virus in these individuals.
- Trial name
- NCT00002078
- Testing
- Interferon alfa-n3
- Where
- 2 sites in United States
- Sponsor
- Purdue Frederick
HIV Infections
A Study of Anti-HIV Monoclonal Antibody KD-247
The purpose of this study is to evaluate the safety and tolerability of 3 infusions of KD-247 over 2 weeks in HIV-1 seropositive individuals; to determine the pharmacokinetic parameters of KD-247 when administered as above; and…
- Trial name
- NCT00917813
- Testing
- KD-247, Physiological saline
- Where
- 15 sites in United States
- Volunteers
- 27 people
- Sponsor
- The Chemo-Sero-Therapeutic Research Institute
HIV Infections
Active Immunization of Asymptomatic, HIV-Infected Individuals With Recombinant GP160 HIV-1 Antigen: A Phase I/II Study of Immunogenicity and Toxicity
To determine the minimal effective (immunogenic) dose of vaccine in asymptomatic HIV-1 seropositive individuals with > 400 cells/mm3 (CD4). To determine the dose-response to a 4 fold escalation of the immunizing dose.
- Trial name
- NCT00000977
- Testing
- gp160 Vaccine (MicroGeneSys)
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Phase I/II, Open Label Study to Evaluate the Antiviral Potential of Combination Zidovudine and 2' 3'-Dideoxyinosine (Didanosine) in Patients With Asymptomatic HIV Disease
To assess the safety and to evaluate the anti-HIV effect of low-, moderate-, and high-dose schedules of zidovudine (AZT) plus didanosine (ddI) versus ddI alone in asymptomatic HIV-infected patients.
- Trial name
- NCT00000656
- Testing
- Zidovudine, Didanosine
- Where
- 5 sites in United States
- Volunteers
- 116 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Vitamin B Therapy for Hyperlactatemia
The purpose of this study is to see if vitamin B can treat mild hyperlactatemia (a higher than normal level of lactate in the blood) in patients who take nucleoside reverse transcriptase inhibitors (NRTIs).
- Trial name
- NCT00031057
- Testing
- Thiamine hydrochloride, Riboflavin
- Where
- 3 sites in United States
- Volunteers
- 225 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Assessment of Asymptomatic Heart Disease in Children With HIV
The purpose of this study is to perform cardiac evaluation in HIV-1 (predominantly clade C)infected children by history, physical examination, echocardiogram and plasma N-terminal pro-B-type natriuretic peptide (N-BNP)measurement…
- Trial name
- NCT00426374
- Testing
- echocardiography and blood test
- Where
- Israel
- Sponsor
- Hadassah Medical Organization
HIV
Screening Strategy for Asymptomatic Sexually Transmitted Infections (STI) in a Cohort of HIV Outpatients Men Who Have Sex With Men (DRIVER)
Comparison of two screening strategies of asymptomatic sexually transmitted infections : routine screening versus screening as reported by the risks taken by the patient, in a cohort of HIV outpatients men who have sex with men.
- Trial name
- DRIVER (NCT02413632)
- Testing
- creation of a STIs score risk, validation of a STIs score risk
- Where
- 17 sites in France
- Volunteers
- 495 people
- Sponsor
- Hopital Foch
Tuberculosis, Tuberculosis (TB)
Questioning the Epidemiology of Asymptomatic TB
Tuberculosis (TB) remains one of the world's leading causes of morbidity and mortality. Current TB control strategies focus largely on the binary paradigm of TB, which tackle Mtb infection and the symptomatic stages of the…
- Conditions
- Tuberculosis, Tuberculosis (TB), HIV, HIV (Human Immunodeficiency Virus)
- Trial name
- TB QUEST (NCT07312266)
- Where
- Mozambique
- Volunteers
- 6,770 people, healthy volunteers welcome
- Sponsor
- Barcelona Institute for Global Health
HIV Infections
A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3
To evaluate the effect of ranitidine on immunologic indicators in asymptomatic HIV-1 infected patients with CD4 counts of 400-700 cells/mm3.
- Trial name
- NCT00002106
- Testing
- Ranitidine hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 104 people
- Sponsor
- Glaxo Wellcome
HIV Infections
A Pilot Study of Immunization With HIV-1 Antigen Pulsed Allogenic Dendritic Cells in HIV-Infected Asymptomatic Patients With CD4+ T Cells > 350 Cells/mm3
To define the safety and efficacy of sibling-supplied, HIV antigen-pulsed dendritic cells in increasing the immune response in HIV-infected patients.
- Trial name
- NCT00001064
- Testing
- Allogenic Dendritic Cells
- Where
- United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV Infection
To determine the safety and immunogenicity of gp160 (MicroGeneSys), rgp120/HIV-1MN (Genentech), and rgp120/HIV-1SF2 (BIOCINE) and their adjuvants in HIV-infected children 1 month to 18 years of age.
- Trial name
- NCT00000762
- Testing
- rgp120/HIV-1MN, rgp120/HIV-1 SF-2, gp160 Vaccine (MicroGeneSys)
- Where
- 34 sites in United States, Puerto Rico
- Volunteers
- 72 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Asymptomatic HIV Infection
Evaluation of the Safety, Efficacy, and Pharmacokinetics of Intravenous Deferiprone in HIV-Positive Subjects
This study will evaluate the safety, tolerability, antiretroviral activity, pharmacokinetics, and pharmacodynamics of an intravenous formulation of deferiprone in HIV-infected subjects.
- Trial name
- NCT02456558
- Testing
- Intravenous deferiprone
- Where
- 2 sites in South Africa
- Volunteers
- 30 people
- Sponsor
- ApoPharma
HIV Infections
Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects
This protocol represents the first in human study of TUTI-16, and is being conducted to establish the safety and human immunogenicity (anti-HIV-1 Tat titers) of subcutaneously administered TUTI-16.
- Trial name
- THYMON-08001 (NCT00848211)
- Testing
- TUTI-16 (0.03mg), TUTI-16 (0.1mg), TUTI-16 (0.6mg)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Thymon, LLC
HIV Infections, Cytomegalovirus
A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.
This was an open-label, controlled study, conducted at US sites to evaluate the anti-inflammatory effectiveness of the study drug letermovir in adults with HIV and asymptomatic cytomegalovirus (CMV) who were on antiretroviral…
- Conditions
- HIV Infections, Cytomegalovirus, CMV
- Trial name
- ELICIT (NCT04840199)
- Testing
- Letermovir Oral Tablet
- Where
- 15 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety and Efficacy of Zidovudine for Asymptomatic HIV-Infected Individuals
To determine if treatment with zidovudine (AZT) will delay or prevent the onset of AIDS or AIDS related complex (ARC) in individuals infected with HIV but who do not have symptoms of AIDS or ARC.
- Trial name
- NCT00000736
- Testing
- Zidovudine
- Where
- 43 sites in United States
- Volunteers
- 3,200 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection Asymptomatic
Synbiotics in Advanced HIV Infection
Late diagnosed HIV-infected subjects show impaired immunological recovery resulting in a greater risk of clinical progression. Gut bacteria metabolism appears to impact immune recovery in HIV-infected subjects, and while…
- Trial name
- PROMALTIA (NCT03009032)
- Testing
- PMT25341
- Volunteers
- 77 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
HIV Infections
Evaluation of the Efficacy of Hydroxychloroquine in Decreasing Immune Activation in Asymptomatic HIV-infected Patients
The purpose of this pilot study is to find out if taking hydroxychloroquine will decrease immune activation (stimulation of the body's defence system) in people with early HIV infection.
- Trial name
- HCQ-01 (NCT01067417)
- Testing
- Hydroxychloroquine
- Volunteers
- 83 people
- Sponsor
- Medical Research Council
HIV Infections
A Phase I Trial of APL 400-003 Vaccine: Safety and Immune Response Evaluations of Multiple Injections at Escalating Doses in Asymptomatic HIV-Infected Patients
To evaluate safety and immune response in HIV-infected patients treated with multiple injections of APL 400-003 vaccine. PER 2/27/96 AMENDMENT: To evaluate the safety of the vaccine when administered via the Biojector 2000…
- Trial name
- NCT00002350
- Testing
- APL 400-003
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Apollon
HIV Infections
An Ascending, Single Oral Dose Pharmacokinetic Study of 3'-Deoxy-3'-Fluorothymidine (FLT) in Asymptomatic Human Immunodeficiency Virus (HIV)-Infected Subjects
To characterize the pharmacokinetics of orally administered 3'-deoxy-3'-fluorothymidine (FLT), in a liquid formulation, after single doses in asymptomatic HIV-infected patients and to assess the safety and tolerance of the single…
- Trial name
- NCT00002271
- Testing
- Alovudine
- Where
- United States
- Sponsor
- Lederle Laboratories
Leishmaniasis, Visceral
Predicting Visceral Leishmaniasis in HIV Infected Patients
In this cohort study, the investigators will study the asymptomatic period preceding the onset of active Visceral Leishmaniasis (VL) in HIV-infected individuals from VL endemic regions in Ethiopia as an avenue to develop an…
- Trial name
- PreLeisH (NCT03013673)
- Testing
- No intervention
- Where
- Ethiopia
- Volunteers
- 566 people
- Sponsor
- Institute of Tropical Medicine, Belgium